You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company began offering testing to clinicians in the first quarter of this year and expects volume to grow significantly over the next several months.
In PLOS this week: yeast modeling of mutations found through MSKCC IMPACT, tumor features associated with presence of circulating DNA, and more.
The team has begun analyzing additional analytes in HER2-positive breast cancer patients and will present preliminary results at AACR's annual meeting in May.
Investigators teased out imaging signals and underlying biology that can differentiate the subset of brain cancers for which tumor DNA can be detected in blood.
In a new study, using larger numbers of patient-specific mutations helped better detect residual disease in breast cancer patients' blood after treatment.
A four-year, $5.5 million program will assess whether circulating cell-free DNA testing can improve diagnosis and outcomes for a type of EBV-associated cancer.
The company has overcome one major hurdle and is poised to clear another in the first half of this year, clearing the way for new test development.
The firm said its revenues for the three months ended Dec. 31, 2019 were $62.9 million compared to $32.9 million in the same quarter of 2018.
Investigators have developed an approach called RAMP-Seq in which targeted radiation of a suspicious lesion vastly increase levels ctDNA, aiding detection and allowing genotyping.
Natera's Signatera test will be used to select and monitor eligible patients with KRAS-mutant tumors who have molecular residual disease after surgery.
The Los Angeles Times reports that experts say Moderna's investigational COVID-19 vaccine results seem to be a step in the right direction, but that more testing is needed.
The Washington Post reports a new coronavirus data reporting protocol goes around the Centers for Disease Control and Prevention.
The Trump Administration has reversed its policy that could have stripped international students of their visas, the New York Times says.
In Cell this week: proteomic and metabolomic analysis of blood from COVID-19 patients, change in phosphorylation with infection, and more.